We are live on ! Find out more
ZVSAW

ZyVersa Therapeutics, Inc. Warrants
ZVSAW

Delisted

ZVSAW was delisted on the 20th of December, 2022.

16 hedge funds and large institutions have $1.84M invested in ZyVersa Therapeutics, Inc. Warrants in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

14% more funds holding

Funds holding: 1416 (+2)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

11% less capital invested

Capital invested by funds: $2.07M → $1.84M (-$230K)

Holders
16
Holders Change
+2
Holders Change %
+14.29%
% of All Funds
0.27%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
1
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change

ZVSAW Hedge Fund Activity: Q2 2022 in Review

16 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q2 2022, worth a combined $1.84M — down 11% from $2.07M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ZVSAW positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was EHP Funds Inc, opening a new position worth an estimated $95K. The largest seller was Cohanzick Management, exiting entirely with an estimated $90K sold.

  • 16 institutional investors held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q2 2022, up from 14 in Q1 2022.
  • Funds reported $1.84M of ZyVersa Therapeutics, Inc. Warrants stock for Q2 2022, down 11% quarter-over-quarter.
  • 5 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q2 2022 and 3 closed out, a net change of +2 holders.
  • The largest ZyVersa Therapeutics, Inc. Warrants buyer in Q2 2022 was EHP Funds Inc, an estimated $95K added.
  • The largest ZyVersa Therapeutics, Inc. Warrants seller in Q2 2022 was Cohanzick Management, an estimated $90K sold.

Based on aggregated 13F filings for Q2 2022.